DELETION 11Q ATM (CLL) LEUKEMIC BLOOD

Deletion 11q ATM (CLL), Leukemic Blood

What it is

The Deletion 11q ATM (CLL), Leukemic Blood test is a cytogenetic and molecular analysis performed on blood samples from patients with chronic lymphocytic leukemia (CLL). It detects deletions on the long arm of chromosome 11 (11q), often involving the ATM gene. This genetic abnormality is clinically significant because it influences how the disease behaves and guides treatment planning.

Uses

This test is used to assess prognosis and treatment strategy in patients with CLL. A deletion in the 11q region is associated with more aggressive disease, bulky lymphadenopathy, and earlier need for therapy. It helps oncologists stratify patient risk, select targeted therapies, and monitor progression.

Symptoms That May Lead to the Test

The test is ordered after a confirmed diagnosis of CLL. It may be specifically recommended if a patient shows signs of progressive disease, such as rapidly enlarging lymph nodes, worsening anemia, frequent infections, fatigue, or increasing white blood cell counts. It is part of the standard cytogenetic and FISH (fluorescence in situ hybridization) panel for CLL evaluation.

Abnormal Results

Positive for 11q Deletion: Indicates a higher-risk form of CLL. Patients may have shorter time to progression, more aggressive disease, and may respond better to newer targeted agents (like BTK or BCL-2 inhibitors) than to traditional chemotherapy.

Negative for 11q Deletion: Suggests absence of this abnormality. Prognosis may be more favorable, but results must be considered along with other genetic markers (e.g., TP53 deletion, IGHV mutation, trisomy 12) to provide a complete risk profile.

Risks

The test requires only a routine blood sample. Risks are minimal and limited to mild discomfort, bruising, or dizziness at the collection site. These side effects are uncommon and temporary.